KR101380128B1 - Ｄｈａ 에스테르 및 심장혈관질환 치료 및 예방을 위한 용도 - Google Patents

Ｄｈａ 에스테르 및 심장혈관질환 치료 및 예방을 위한 용도 Download PDF

Info

Publication number
KR101380128B1
KR101380128B1 KR1020097001053A KR20097001053A KR101380128B1 KR 101380128 B1 KR101380128 B1 KR 101380128B1 KR 1020097001053 A KR1020097001053 A KR 1020097001053A KR 20097001053 A KR20097001053 A KR 20097001053A KR 101380128 B1 KR101380128 B1 KR 101380128B1
Authority
KR
South Korea
Prior art keywords
treatment
prevention
dha
reaction
docosahexaenoic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020097001053A
Other languages
English (en)
Korean (ko)
Other versions
KR20090024794A (ko
Inventor
프레데리끄 쁘렝
앙드레 드롱
쟝 갈데뜨
쟝 프랑끄와 파뜨와쏘
아렝 마르띠
에띠앙느 쓰쁘락
Original Assignee
피에르 파브르 메디카먼트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37686083&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101380128(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 피에르 파브르 메디카먼트 filed Critical 피에르 파브르 메디카먼트
Publication of KR20090024794A publication Critical patent/KR20090024794A/ko
Application granted granted Critical
Publication of KR101380128B1 publication Critical patent/KR101380128B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/587—Monocarboxylic acid esters having at least two carbon-to-carbon double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/02—Preparation of carboxylic acid esters by interreacting ester groups, i.e. transesterification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020097001053A 2006-06-23 2007-06-22 Ｄｈａ 에스테르 및 심장혈관질환 치료 및 예방을 위한 용도 Expired - Fee Related KR101380128B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0605649 2006-06-23
FR0605649A FR2902659A1 (fr) 2006-06-23 2006-06-23 Ester de dha et son utilisation dans le traitement et la prevention des maladies cardiovasculaires
PCT/EP2007/056277 WO2007147899A2 (en) 2006-06-23 2007-06-22 Dha esters and use thereof in treatment and prevention of cardiovascular disease

Publications (2)

Publication Number Publication Date
KR20090024794A KR20090024794A (ko) 2009-03-09
KR101380128B1 true KR101380128B1 (ko) 2014-04-11

Family

ID=37686083

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097001053A Expired - Fee Related KR101380128B1 (ko) 2006-06-23 2007-06-22 Ｄｈａ 에스테르 및 심장혈관질환 치료 및 예방을 위한 용도

Country Status (38)

Country Link
US (2) US8034377B2 (https=)
EP (1) EP2034999B9 (https=)
JP (1) JP5053372B2 (https=)
KR (1) KR101380128B1 (https=)
CN (1) CN101472590A (https=)
AR (1) AR061622A1 (https=)
AT (1) ATE489091T1 (https=)
AU (1) AU2007262958B2 (https=)
BR (1) BRPI0713725A2 (https=)
CA (1) CA2655570C (https=)
CL (1) CL2010001123A1 (https=)
CO (1) CO6150156A2 (https=)
CR (1) CR10507A (https=)
DE (1) DE602007010776D1 (https=)
DK (1) DK2034999T3 (https=)
EC (1) ECSP099039A (https=)
ES (1) ES2355611T3 (https=)
FR (1) FR2902659A1 (https=)
GE (1) GEP20125464B (https=)
HN (1) HN2008001771A (https=)
HR (1) HRP20110086T1 (https=)
IL (1) IL195562A (https=)
MA (1) MA30584B1 (https=)
MX (1) MX2009000103A (https=)
MY (1) MY145985A (https=)
NO (1) NO20090334L (https=)
NZ (1) NZ573454A (https=)
PL (1) PL2034999T3 (https=)
PT (1) PT2034999E (https=)
RS (1) RS51629B (https=)
RU (1) RU2451672C2 (https=)
SA (1) SA07280345B1 (https=)
SI (1) SI2034999T1 (https=)
TN (1) TNSN08527A1 (https=)
TW (1) TWI389888B (https=)
UA (1) UA96156C2 (https=)
WO (1) WO2007147899A2 (https=)
ZA (1) ZA200900334B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2334536B1 (es) * 2008-04-11 2011-01-24 Universidad Complutense De Madrid Procedimiento para la obtencion selectiva de 12-hidroxi-9-cis-octadecenoato de (1,4:3,6-dianhidro-d-glucitol) utilizando lipasas inmovilizadas como catalizador.
FR2949063B1 (fr) * 2009-08-11 2011-09-30 Pf Medicament Composition pharmaceutique comprenant un ester de dha destinee a etre administree par voie parenterale
KR102167261B1 (ko) * 2010-06-18 2020-10-20 엑스바이오테크, 인크. 관절염 치료
FR2963790B1 (fr) * 2010-08-11 2012-09-28 Pf Medicament Docosahexaeneoate de panthenyle et son utilisation dans le traitement et la prevention des maladies cardiovasculaires
US10294296B2 (en) 2010-08-23 2019-05-21 Xbiotech, Inc. Treatment for neoplastic diseases
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
CN102757444B (zh) * 2011-04-29 2016-02-10 南京信诺泰医药有限公司 具有一氧化氮供体性质的苯并呋喃类化合物
FR2998479B1 (fr) * 2012-11-27 2017-04-28 Pf Medicament Utilisation d'un ester de dha pour le traitement prophylactique et/ou curatif de la drepanocytose
WO2016024283A1 (en) * 2014-08-12 2016-02-18 Praj Industries Limited Process for the preparation of triglycerides of epa and dha
US10441087B2 (en) 2015-02-24 2019-10-15 Sleep Number Corporation Mattress with adjustable firmness
CA3053231A1 (en) 2017-02-16 2018-08-23 Xbiotech Inc. Treatment of hidradenitis suppurativa
EP3582791A4 (en) * 2017-02-20 2021-03-31 The Board of Supervisors of Louisiana State University and Agricultural and Mechanical College HYDROGEN SULPHIDE AND / OR NITRITE IN THE TREATMENT AND PREVENTION OF ATRIAL FIBRILLATION
CN110950881A (zh) * 2018-09-27 2020-04-03 中国科学院上海药物研究所 一类三环类似物、其制备方法和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6034947A (ja) * 1983-08-05 1985-02-22 Terumo Corp ドコサヘキサエン酸誘導体およびそれを用いた血小板凝集阻止剤

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL133049C (https=) 1966-02-24
JPS5967263A (ja) 1982-10-07 1984-04-16 Terumo Corp ペンタエン高級脂肪酸ピリジルアルコ−ルエステルおよびその製法
JPS5967264A (ja) 1982-10-08 1984-04-16 Terumo Corp 血小板凝集抑制剤
JPS59502024A (ja) 1982-11-16 1984-12-06 イレナ　モッチャン　マルス リュウマチ性疾病治療剤
GB9300125D0 (en) * 1993-01-06 1993-03-03 Scotia Holdings Plc Compositions containing esters of unsaturated fatty acids
US5760081A (en) 1994-05-10 1998-06-02 The General Hospital Corporation Omega 3 fatty acids in the prevention of ventricular fibrillation
US6015821A (en) 1995-05-01 2000-01-18 Horrobin; David Frederick Nicotinic acid esters and pharmaceutical compositions containing them
IL118092A0 (en) 1995-05-03 1996-09-12 Smithkline Beecham Plc Antibacterial compounds their preparation and pharmaceutical compositions containing them
US5919815A (en) 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
AUPQ480399A0 (en) 1999-12-22 2000-02-03 Commonwealth Scientific And Industrial Research Organisation Unsaturated fatty acids and their uses in therapy
ATE305810T1 (de) 2000-05-22 2005-10-15 Pro Aparts Investimentos E Con Fettsäure enthaltende pharmazeutische zusammensetzung die wenigstens 80 gew. epa und dha enthält
ITMI20010129A1 (it) 2001-01-25 2002-07-25 Pharmacia & Upjohn Spa Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
US7704542B2 (en) * 2001-09-12 2010-04-27 Xanodyne Pharmaceuticals, Inc. Vitamin/mineral compositions with DHA
US8729124B2 (en) 2002-03-05 2014-05-20 Pronova Biopharma Norge As Use of EPA and DHA in secondary prevention
ITMI20022511A1 (it) * 2002-11-26 2004-05-27 Victorix Assets Ltd Uso di composizioni farmaceutiche contenenti esteri etilici di acidi poliinsaturi omega-3 nella orevenzione della fibrillazione atriale.
EP1466597A1 (en) * 2003-04-07 2004-10-13 Clinigenetics Use of dha esters to control or prevent cardiovascular diseases
WO2004091603A1 (fr) * 2003-04-07 2004-10-28 Clinigenetics Utilisation d’un ester de dha pour le traitement des malades cardiovasculaires
CN1774179A (zh) 2003-04-17 2006-05-17 贝林格尔.英格海姆国际有限公司 供孕妇用的多种维生素及矿物质补充品

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6034947A (ja) * 1983-08-05 1985-02-22 Terumo Corp ドコサヘキサエン酸誘導体およびそれを用いた血小板凝集阻止剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Harvey et al. Biomedical Mass Spectrometry, 1984, vol.11, no.7, p.340-347 *
Torres et al. Tetrahedron, 2005, vol.62, no.32, p.7654-7660 *

Also Published As

Publication number Publication date
EP2034999B1 (en) 2010-11-24
ATE489091T1 (de) 2010-12-15
EP2034999B9 (en) 2011-03-09
KR20090024794A (ko) 2009-03-09
RU2008152248A (ru) 2010-07-27
FR2902659A1 (fr) 2007-12-28
GEP20125464B (en) 2012-04-10
CL2010001123A1 (es) 2011-03-25
US8034377B2 (en) 2011-10-11
TNSN08527A1 (en) 2010-04-14
WO2007147899A3 (en) 2008-03-13
TWI389888B (zh) 2013-03-21
MX2009000103A (es) 2009-01-23
IL195562A (en) 2012-06-28
DK2034999T3 (da) 2011-01-24
PL2034999T3 (pl) 2011-05-31
BRPI0713725A2 (pt) 2012-10-30
AU2007262958B2 (en) 2011-10-27
WO2007147899A2 (en) 2007-12-27
ES2355611T3 (es) 2011-03-29
AR061622A1 (es) 2008-09-10
AU2007262958A1 (en) 2007-12-27
ZA200900334B (en) 2009-12-30
CA2655570A1 (en) 2007-12-27
IL195562A0 (en) 2009-09-01
US20090312354A1 (en) 2009-12-17
DE602007010776D1 (de) 2011-01-05
MY145985A (en) 2012-05-31
UA96156C2 (ru) 2011-10-10
HRP20110086T1 (hr) 2011-03-31
MA30584B1 (fr) 2009-07-01
CO6150156A2 (es) 2010-04-20
NO20090334L (no) 2009-03-04
TW200811108A (en) 2008-03-01
EP2034999A2 (en) 2009-03-18
JP2009544576A (ja) 2009-12-17
WO2007147899B1 (en) 2008-05-02
NZ573454A (en) 2010-10-29
CR10507A (es) 2009-02-05
SI2034999T1 (sl) 2011-02-28
US20110237613A1 (en) 2011-09-29
PT2034999E (pt) 2011-01-19
HN2008001771A (es) 2011-01-24
CA2655570C (en) 2015-09-08
JP5053372B2 (ja) 2012-10-17
US8227479B2 (en) 2012-07-24
ECSP099039A (es) 2009-02-27
RU2451672C2 (ru) 2012-05-27
CN101472590A (zh) 2009-07-01
RS51629B (sr) 2011-08-31
SA07280345B1 (ar) 2011-01-15

Similar Documents

Publication Publication Date Title
KR101380128B1 (ko) Ｄｈａ 에스테르 및 심장혈관질환 치료 및 예방을 위한 용도
EP0387000A2 (en) Medicament for the treatment of thrombus, inflammation and high blood pressure
SK14322002A3 (sk) Percyquinnin, spôsob jeho prípravy, organizmus na tento spôsob a farmaceutická kompozícia obsahujúca Percyquinnin
JP2000514801A (ja) 抗高血圧、心臓保護、抗乏血及び抗脂肪分解特性を有する化合物
JPH06279311A (ja) プロテインキナーゼｃアイソザイムの活性化剤
US10064853B2 (en) Compounds for use in methods for treating diseases or conditions mediated by protein disulfide isomerase
Holland et al. Biocatalytic and chemical routes to all the stereoisomers of methionine and ethionine sulfoxides
US4595681A (en) Antihypertensive neutral lipid
EP0773949B1 (fr) Esters du d-mannose ou du xylitol et leur utilisation comme medicaments
HK1131563A (en) Dha esters and use thereof in treatment and prevention of cardiovascular disease
KR100577320B1 (ko) 아실 코에이:디아실글리세롤 아실트랜스퍼라제 활성 저해제인 퀴놀론 알칼로이드 화합물을 유효성분으로 함유하는 중성지방 강하제
KR20070011288A (ko) Ａｂｃａ1 안정화제
KR101512486B1 (ko) 피리피로펜 ｓ 및 그의 제조방법
CN115873057A (zh) 油杉中26-羧酸三萜化合物及其制备和作为乙酰辅酶a羧化酶抑制剂的用途
EP2655390A2 (en) Purified cardiogenin isomer and related methods
KR20010012299A (ko) 신규 헤테로고리 화합물
JPH06135984A (ja) トリメチロールプロパン含有糖脂質
JPS61291593A (ja) コレステロ−ルエステル分解活性促進効果を有する物質
JPS6323188B2 (https=)

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20170227

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20180327

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20180327

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000